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To the Editor: Anaerobic bacteria (anaerobes) are the predominant 
flora on human skin and mucous membranes and are a common 
cause of endogenous infections. Anaerobes are commonly found in 
polymicrobial infections in combination with aerobes, and in this 
setting therapy should be directed towards both types of pathogens. 
Antibiotic resistance among anaerobes has increased, and antibiotics 
that were reliably effective, such as metronidazole, are no longer as 
active.1 Since culture of anaerobes is not within the scope of many 
laboratories, susceptibility testing is not routinely performed.
We prospectively studied antibiotic susceptibility profiles 
of anaerobes isolated from clinical specimens routinely tested in 
the microbiology laboratory at Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH) from June 2005 until February 2007. 
Our objectives were to determine the antimicrobial susceptibility 
patterns of anaerobes isolated from clinical specimens, initiate 
a surveillance programme to monitor the susceptibility profiles 
of anaerobes, and identify their changing trends in antibiotic 
susceptibility and resistance.
Specimens from patients with suspected mixed aerobic/anaerobic 
infections were submitted in anaerobic transport media to the 
microbiology laboratory, where microscopy, culture and susceptibility 
testing to amoxicillin-clavulanate, clindamycin, metronidazole, 
benzylpenicillin, ertapenem, cefoxitin, ceftriaxone, chloramphenicol 
and piperacillin-tazobactam were performed. Antimicrobial 
susceptibility testing to record the minimum inhibitory concentration 
(MIC) profile was performed on all isolates using the E test® strip 
method according to the manufacturer’s instructions. Interpretation 
of the MIC was performed using the Clinical and Laboratory 
Standards Institute (CLSI) guidelines.2
Quality control was performed with organisms of known 
susceptibility. Control strains used were Bacteroides fragilis ATCC 
25285, B. thetaiotaomicron ATCC 29741 and Eubacterium lentum 
ATCC 43055. All isolates were processed according to standard 
operating procedures (SOPs) established at the CMJAH Microbiology 
Laboratory. Anaerobes were identified using the Finegold system, 
which included selective growth media, biochemical profiles and 
susceptibility to antimicrobial agents, and by the use of rapid ID 32A 
API panels.12 Statistical analysis was performed using the WHONET 
5.4 programme.
Anaerobes were submitted from 165 patients (139 adults, 18 
children, 8 unknown age); all 180 anaerobes were identified to species 
level, with B. fragilis being the most common. Most specimens were 
submitted from surgical wards (29%), emergency room (17%), 
general ICU (10%) and gynaecology (6%).
The most active agents against these organisms were 
chloramphenicol (100% of isolates susceptible), ertapenem (97.2%), 
piperacillin-tazobactam (99.4%) and amoxicillin-clavulanate (96.7%). 
Less active were metronidazole (89.4%), cefoxitin (85%), clindamycin 
(81.7%), ceftriaxone (68.3%) and penicillin (33.3%) (Fig. 1). Table I 
presents the MIC50 and MIC90 and the susceptibility ranges.
Organisms within the B. fragilis group were isolated from 97 
patients (54%), comprising B. fragilis (81), B. thetaiotaomicron, 
(4), B. distasonis (1), B. ovatus (5), B. vulgatus (3), B. eggerthii 
(1), B. uniformis (1) and Bacteroides spp. (1). Overall this group 
demonstrated 13.4% resistance to metronidazole.
Anaerobic organisms such as B. fragilis 81 (45%), Clostridium 
perfringens 23 (13%), Peptostreptococcus anaerobius 14 (8%) 
and Prevotella melaninogenica 14 (8%) were analysed separately. 
Chloramphenicol, piperacillin-tazobactam, ertapenem and 
amoxicillin-clavulanate demonstrated the highest activity against 
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these isolates, while 11% and 18% demonstrated resistance to 
metronidazole and clindamycin, respectively.
Discussion
Our study illustrates the dynamic changes in antimicrobial 
susceptibility that have occurred among anaerobes and emphasises 
a decrease in antimicrobial susceptibility compared with a survey 
in Cape Town in 1995.8 Of particular concern is the prevalence of 
metronidazole resistance that is largely unrecognised by clinicians. 
Susceptibility profiles of B. fragilis were similar to those from 
Brazil,4 demonstrating resistance rates of 12% for cefoxitin, 15.1% 
for cefotaxime, 1% for chloramphenicol, 18.2% for clindamycin, 
75.7% for tetracycline and 16% for metronidazole. In our study, 
resistance to cefoxitin was 8.6%, to clindamycin 14.8% and to 
metronidazole 12.3%, but there was no resistance to chloramphenicol 
or amoxicillin-clavulanate. Others5,6 have reported clindamycin 
resistance rates as high as 33% in B. fragilis, and 36%, 49% and 46% 
in B. thetaiotamicron, B. distasonis and B. caccae, respectively. Oteo 
et al.7 reported an overall resistance rate of 49% to clindamycin for 
the B. fragilis group, while in our study resistance to clindamycin 
was 18.7%.
A Cape Town study8 demonstrated that 4% (total 26) 
of C. perfringens isolates were resistant to benzylpenicillin and 
clindamycin, but all were sensitive to cefoxitin, metronidazole, 
chloramphenicol and amoxicillin-clavulanate. C. perfringens, C. 
fallax and C. sordelli in this study exhibited no resistance to penicillin 
or metronidazole, while the single isolate of C. septicum showed high-
level resistance to metronidazole (MIC 256 μg/ml).The single isolate 
of C. paraputrificum was resistant to clindamycin (MIC 128 μg/ml) 
and cefoxitin (MIC 256 μg/ml).
P. melaninogenica (15 isolates) were resistant to penicillin and 
metronidazole in 60% and 6.7%, respectively. Two isolates of 
Veillonella parvula were resistant to penicillin.
Among all isolated anaerobic organisms, 97.2% were susceptible 
to ertapenem. This was similar to the findings of Goldstein et al.,9 
who demonstrated that ertapenem was consistently active against 
the B. fragilis group, but not against 12 (20%) of strains of Bilophila 
wadsworthia, 3 (5%)  lactobacilli, and 1 Acidaminococcus fermentans.
Pfister prospectively investigated 370 clinical isolates of anaerobic 
bacteria over 6 months.10 With the exception of one isolate of 
Fusobacterium varium and B. fragilis (MIC 32 μg/ml), all were also 
sensitive to ertapenem.
In our study, among 20 strains of peptostreptococci, 35% were 
resistant to penicillin and 5% to clindamycin, with no resistance 
to metronidazole. In contrast, in Koch et al.’s study,8 10% of 20 
strains of P. anaerobius were resistant to benzylpenicillin, cefoxitin 
and metronidazole; in addition Peptostreptococcus spp. (total of 17) 
showed resistance to benzylpenicillin in 12% and to metronidazole 
and clindamycin in 6%, respectively.
Appelbaum and Chatterton11 in 1978, in a study similar to that 
in South Africa on 265 anaerobic bacteria from clinical isolates, 
found low levels of resistance to penicillin, chloramphenicol, 
clindamycin and metronidazole. However, in our study 100% remain 
susceptible to chloramphenicol, but only 82% to clindamycin, 89% to 
metronidazole and 33% to penicillin.
Conclusion
We demonstrated a worrying increase in resistance to metronidazole, 
particularly in the B. fragilis group, and highlight the high rates 
of intermediate susceptibility to other anti-anaerobic agents. This 
emphasises the necessity for periodic active surveillance to identify 
and record these emerging trends.
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Table I. In vitro activity of antimicrobial agents against 180 
isolated anaerobic organisms
Antibiotic (breakpoint of 
susceptibility, μg/ml)
MIC μg/ml Susceptibility
50% 90% Range (%)
Penicillin (<0.5) 12 32 0.002 - 256 33
Cefoxitin (< 16) 3 32 0.016 - 256 85
Ceftriaxone (<16) 3 32 0.002 - 256 68
Amoxicillin/clavulanate 
(<4) 0.19 1 0.016 - 96 97
Piperacillin/tazobactam 
(<32) 0.19 4 0.016 - 256 99
Ertapenem (<4) 0.125 1.5 0.002 - 32 97
Clindamycin  (<2) 0.19 256 0.016 - 256 82
Chloramphenicol (<8) 1 2 0.016 - 8 100
Metronidazole (<8) 0.5 16 0.016 - 256 89
Fig. 1. Antimicrobial activities of 9 agents against all 180 anaerobic organ-
isms.
